SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following its latest update, which showcased substantial revenue growth and accelerating global expansion of its ANKTIVA cancer therapy, sparking community discussion around potential expedited regulatory approvals and a significant short squeeze opportunity amid high after-hours volatility.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is seeing intense trading and sharp declines despite broader energy sector rallies and surging crude oil prices driven by escalating Middle East tensions. The community is fiercely debating whether this extreme volatility stems from active dilution and market manipulation or is a massive shakeout positioning the low-float stock for a potential short squeeze, reminiscent of its historical explosive movements during geopolitical events.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike is trending following its recent earnings report, which delivered a narrow beat and generally in-line guidance, sparking a heated community debate between those who view it as a leading cybersecurity platform poised to benefit from AI and rising geopolitical tensions, and others who contend its valuation remains excessively high despite analyst upgrades.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is experiencing a surge in community engagement and price momentum, with enthusiasts rallying around its 'culture coin' identity on Solana and anticipating further growth leading up to the seasonal 4/20 event, as many highlight its consistent progress and long-term potential.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is surging amid a flurry of positive developments, including a significant settlement in its patent dispute with Arbutus Biopharma and Genevant, the FDA's reversal to review its seasonal flu vaccine, and a European recommendation for its COVID-19/flu combination shot, driving strong community optimism for its pipeline and a potential short squeeze.

GitLab, Inc. engages in the intelligent DevSecOps platform for software innovation. The firm enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

Gitlab is trending as investors react to its latest financial report, which, despite beating recent revenue and EPS figures, presented weaker-than-anticipated forward guidance, sparking a polarized discussion about its growth trajectory and high stock-based compensation amid broader software sector concerns and persistent buyout speculation.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics Inc. is trending following its transformative acquisition of Covelya Group, significantly expanding its global footprint in subsea technology and positioning it as a major supplier for defense and commercial sectors. The community is actively discussing potential short-term share dilution from a public offering against robust long-term growth potential and strategic partnerships within the burgeoning underwater robotics sector.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is surging as escalating Middle East tensions halt Qatar's LNG production and disrupt the Strait of Hormuz, driving global natural gas prices dramatically higher. This geopolitical "perfect storm," combined with a strong earnings beat and a favorable legal outcome against Shell, positions the company as a key beneficiary, fueling community discussion around potential short squeezes and its undervalued status.

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending as it achieves new all-time highs on notable trading volume and significant inflows, showcasing strong outperformance against international equities. Community discussion highlights optimism for the ETF as a core long-term holding, reflecting robust U.S. market momentum.

Ross Stores, Inc. engages in the operation of off-price retail apparel and home accessories stores. Its products include branded and designer apparel, accessories, footwear, and home fashions through the Dress for Less and dd's DISCOUNTS brands. The company was founded by Stuart G. Moldaw in 1957 and is headquartered in Dublin, CA.

Ross Stores, Inc.

Ross Stores is trending after reporting a significant Q4 earnings beat and robust Q1 sales outlook, fueled by strong customer response and operational improvements, though community conversation remains divided on whether the future guidance justifies its current valuation amidst a value-seeking consumer environment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Moderna Stock Jumps 10% After Hours: Here's Why

Moderna shares are rising in Tuesday's after-hours session after the company announced it reached a settlement agreement.read more...

Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus

(RTTNews) - Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary of Roivant...

<ul class="summary-bullets"><li>Moderna said that the settlement provides certainty going forward for the company’s entire infectious disease portfolio and its future vaccine pipeline with no future royalties owed.&nbsp;</li><li>Under the deal, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026.</li><li>The remaining $1.3 billion payout is subject to further litigation.</li></ul>Shares of vaccine maker Moderna (MRNA) rallied after hours on Tuesday after the company announced that it has entered into an up to $2.25 billion settlement with Genevant Sciences and Arbutus Biopharma.The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ Lipid Nanoparticle (LNP) delivery technology in its COVID-19 vaccine Spikevax as well as respiratory syncytial virus (RSV) vaccine mRESVIA. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=5178901572623640&amp;symbol=MRNA">said</a> that the settlement provides certainty going forward for the company’s entire infectious disease portfolio and its future vaccine pipeline with no future royalties owed.<a href="https://stocktwits.com/symbol/ABUS">Shares of Arbutus</a> fell 8% after hours at the time of writing while shares of Genevant’s parent <a href="https://stocktwits.com/symbol/ROIV">Roivant Sciences</a> gained nearly 1%. Meanwhile, shares of MRNA rallied 11%.<h2 class="st-heading-2">Settlement Agreement</h2>Under the deal, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026. The remaining $1.3 billion is subject to further litigation. If Moderna prevails in the litigation, no further payments will be due but if it doesn't, it will have to make an additional payment of up to $1.3 billion."Resolving this legacy matter from our pandemic response removes uncertainty and allows us to turn our full focus to Moderna's exciting near-term future," said Moderna CEO Stéphane Bancel.The company now expects to end the year with $4.5 to $5.0 billion in cash and cash equivalents. The total projected liquidity available to the company at the end of 2026 will be $5.4 to $5.9 billion, it added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRNA rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/MRNA">MRNA shares</a> have gained nearly 65% over the past 12 months. Meanwhile, ABUS and ROIV added 37% and 174%, respectively.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/autozone-shares-dive-post-earnings-but-wells-fargo-sees-buying-opportunity/cZdeYkuRIPt">AutoZone Shares Dive Post-Earnings But Wells Fargo Sees A Buying Opportunity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration vials of vaccines for coronavirus (COVID-19). Vaccines from left to right, Moderna, Bimervax, Comirnaty and Pfizer BioNTech. (Photo Illustration by Marcos del Mazo/LightRocket via Getty Images)

MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row

The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccine Spikevax.

Equity

The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccine Spikevax.


Top Biotech Stocks To Watch Now - March 3rd

Danaher, Moderna, and Vertex Pharmaceuticals are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that research, develop...

Biotech Stocks To Follow Today - March 2nd

Danaher, Moderna, and ImmunityBio are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that research, develop, and...

MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot

Moderna jumps 4% after EU panel backs mCombriax, its COVID-19-flu combo shot, with phase III data showing stronger immune response vs standalone vaccines.

Promising Biotech Stocks To Research - March 1st

Danaher, Vertex Pharmaceuticals, Moderna, argenex, United Therapeutics, ImmunityBio, and Medpace are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

Biotech Stocks To Keep An Eye On - February 28th

Danaher, Vertex Pharmaceuticals, and Moderna are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that research, develop...

This Is What Whales Are Betting On Moderna

Promising Biotech Stocks To Consider - February 27th

Danaher, Vertex Pharmaceuticals, argenex, ImmunityBio, and Moderna are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly...

Software / SaaS

Cybersecurity

Cloud Infrastructure

AI / Semiconductors

Which beaten-down sector are you buying first?

Stocktwits

Stocktwits Polls

The company settled its patent dispute with Arbutus and Genevant for $950 million upfront and potential future payments, removing litigation uncertainty.

European regulators recommended approval for the company's first-to-market COVID-19 and flu combination vaccine, mCombriax, driving shares higher.

Traders and analysts are eyeing new highs, with price targets ranging from $75 to $200+ following recent positive catalysts.

MRNA
Moderna Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRNA News

MRNAModerna Inc